Accumulating nanoparticles by EPR: A route of no return

Journal of Controlled Release

Volumn 238, Issue , 2016, Pages 58-70

  Ngoune, Romeo ^a   Peters, Annette ^a   von Elverfeldt, Dominik ^a   Winkler, Karl ^a   Pütz, Gerhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

EPR; In vivo imaging; PLD; Therapeutic plasmapheresis; Tumor

Indexed keywords

BLOOD; FLUORESCENCE; HISTOLOGY; LIPOSOMES; NANOPARTICLES; PARAMAGNETIC RESONANCE; PULSED LASER DEPOSITION; TUMORS;

ANTI-CANCER THERAPIES; BLOOD CONCENTRATIONS; ENHANCED PERMEABILITY AND RETENTION EFFECTS; IN-VIVO IMAGING; LONG-TERM RETENTION; THERAPEUTIC PLASMAPHERESIS; TISSUE ACCUMULATION; VASCULAR STRUCTURES;

TISSUE;

HIGH DENSITY LIPOPROTEIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; PLASMA PROTEIN FRACTION; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BREAST TUMOR; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; ENHANCED PERMEABILITY AND RETENTION EFFECT; FEMALE; FLUORESCENCE IMAGING; GEL PERMEATION CHROMATOGRAPHY; MACROPHAGE; MONONUCLEAR PHAGOCYTE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PLASMAPHERESIS; PRIORITY JOURNAL; RAT; TUMOR MODEL; ANIMAL; FISCHER 344 RAT; METABOLISM; NEOPLASM; PERMEABILITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; LIPOSOMES; NANOPARTICLES; NEOPLASMS; OPTICAL IMAGING; PERMEABILITY; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 84979503582     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.07.028     Document Type: Article

References (40)

1. [1] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46 (1986), 6387–6392.
2. [2] Maeda, H., Tsukigawa, K., Fang, J., A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy—problems, solutions, and prospects. Microcirculation 23 (2016), 173–182, 10.1111/micc.12228.
3. [3] Maeda, H., Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 164 (2012), 138–144, 10.1016/j.jconrel.2012.04.038.
4. [4] Taurin, S., Nehoff, H., Greish, K., Anticancer nanomedicine and tumor vascular permeability; where is the missing link?. J. Control. Release 164 (2012), 265–275, 10.1016/j.jconrel.2012.07.013.
5. [5] Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K., McDonald, D.M., Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156 (2000), 1363–1380, 10.1016/S0002-9440(10)65006-7.
6. [6] Ekdawi, S.N., Stewart, J.M.P., Dunne, M., Stapleton, S., Mitsakakis, N., Dou, Y.N., Jaffray, D.A., Allen, C., Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model. J. Control. Release 207 (2015), 101–111, 10.1016/j.jconrel.2015.04.006.
7. [7] Yuan, F., Leunig, M., Huang, S.K., Berk, D.A., Papahadjopoulos, D., Jain, R.K., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54 (1994), 3352–3356.
8. [8] Charrois, G.J.R., Allen, T.M., Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J. Pharmacol. Exp. Ther. 306 (2003), 1058–1067, 10.1124/jpet.103.053413.
9. [9] Northfelt, D.W., Martin, F.J., Working, P., Volberding, P.A., Russell, J., Newman, M., Amantea, M.A., Kaplan, L.D., Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36 (1996), 55–63, 10.1002/j.1552-4604.1996.tb04152.x.
10. [10] Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000), 271–284, 10.1016/S0168-3659(99)00248-5.
11. [11] Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., Maeda, H., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 (1998), 307–314, 10.1111/j.1349-7006.1998.tb00563.x.
12. [12] Harrington, K.J., Rowlinson-Busza, G., Syrigos, K.N., Uster, P.S., Abra, R.M., Stewart, J.S.W., Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br. J. Cancer 83 (2000), 232–238, 10.1054/bjoc.1999.1232.
13. [13] Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., Papahadjopoulos, D., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999), 691–744.
14. [14] Pütz, G., Schmah, O., Eckes, J., Hug, M.J., Winkler, K., Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy. Med. Hypotheses 72 (2009), 393–397, 10.1016/j.mehy.2008.11.027.
15. [15] Sanchez, A.P., Cunard, R., Ward, D.M., The selective therapeutic apheresis procedures. J. Clin. Apher. 28 (2013), 20–29, 10.1002/jca.21265.
16. [16] Pütz, G., Eckes, J., Schmah, O., Winkler, K., Wieland, H., Elimination of liposomes by different separation principles used in low-density lipoprotein apheresis. Ther. Apher. Dial. 12 (2008), 2–12, 10.1111/j.1744-9987.2007.00535.x.
17. [17] Eckes, J., Schmah, O., Siebers, J.W., Groh, U., Zschiedrich, S., Rautenberg, B., Hasenburg, A., Jansen, M., Hug, M.J., Winkler, K., Putz, G., Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer, 11, 2011, 337, 10.1186/1471-2407-11-337.
18. [18] Charrois, G.J.R., Allen, T.M., Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim. Biophys. Acta Biomembr. 1609 (2003), 102–108, 10.1016/S0005-2736(02)00661-2.
19. [19] Hagtvet, E., Evjen, T.J., Nilssen, E.A., Olsen, D.R., Assessment of liposome biodistribution by non-invasive optical imaging: a feasibility study in tumour-bearing mice. J. Nanosci. Nanotechnol. 12 (2012), 2912–2918, 10.1166/jnn.2012.5852.
20. [20] Fang, J., Liao, L., Yin, H., Nakamura, H., Subr, V., Ulbrich, K., Maeda, H., Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin. Future Sci. OA, 1, 2015, 10.4155/fso.15.2.
21. [21] MacDonald, R.C., MacDonald, R.I., Menco, B.P.M., Takeshita, K., Subbarao, N.K., Hu, L., Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim. Biophys. Acta Biomembr. 1061 (1991), 297–303, 10.1016/0005-2736(91)90295-J.
22. [22] Stewart, J.C.M., Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104 (1980), 10–14, 10.1016/0003-2697(80)90269-9.
23. [23] März, W., Siekmeier, R., Scharnagl, H., Seiffert, U.B., Gross, W., Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins. Clin. Chem. 39 (1993), 2276–2281.
24. [24] Maeda, H., Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 88 (2012), 53–71, 10.2183/pjab.88.53.
25. [25] Ho, K.S., Poon, P.C., Owen, S.C., Shoichet, M.S., Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours. BMC Cancer, 12, 2012, 579, 10.1186/1471-2407-12-579.
26. [26] Park, C.M., Goo, J.M., Lee, H.J., Kim, M.A., Kim, H.-C., Kim, K.G., Lee, C.H., Im, J.-G., FN13762 murine breast cancer: region-by-region correlation of first-pass perfusion CT indexes with histologic vascular parameters. Radiology 251 (2009), 721–730, 10.1148/radiol.2513081215.
27. [27] Choi, J.W., Kim, H.-C., Baek, S.Y., Ryu, Y.J., Chung, J.W., A metastatic hepatoma model of rats using the 13762-MAT-B-III cell line: basic characteristics and potential as a tool for interventional oncology experiments. Anticancer Res. 35 (2015), 1333–1338.
28. [28] Karathanasis, E., Chan, L., Karumbaiah, L., McNeeley, K., D'Orsi, C.J., Annapragada, A.V., Sechopoulos, I., Bellamkonda, R.V., Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS One, 4, 2009, e5843, 10.1371/journal.pone.0005843.
29. [29] Yang, X., Knopp, M.V., Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J. Biomed. Biotechnol., 2011, 2011, 10.1155/2011/732848.
30. [30] Harrington, K.J., Mohammadtaghi, S., Uster, P.S., Glass, D., Peters, A.M., Vile, R.G., Stewart, J.S.W., Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7 (2001), 243–254.
31. [31] Maeda, H., Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91 (2015), 3–6, 10.1016/j.addr.2015.01.002.
32. [32] Gabizon, A., Goren, D., Horowitz, A.T., Tzemach, D., Lossos, A., Siegal, T., Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev. 24 (1997), 337–344, 10.1016/S0169-409X(96)00476-0.
33. [33] Heppner, G.H., Tumor heterogeneity. Cancer Res. 44 (1984), 2259–2265.
34. [34] Follette, D.B., Kerr, D., Nasca, T.J., Euler, H.H., Pinevich, A.J., A method for chronic membrane plasmapheresis in the rat. J. Appl. Physiol. 75 (1993), 2820–2824.
35. [35] Debbage, P.L., Griebel, J., Ried, M., Gneiting, T., DeVries, A., Hutzler, P., Lectin intravital perfusion studies in tumor-bearing mice: micrometer-resolution, wide-area mapping of microvascular labeling, distinguishing efficiently and inefficiently perfused microregions in the tumor. J. Histochem. Cytochem. 46 (1998), 627–639, 10.1177/002215549804600508.
36. [36] Kwon, I.K., Lee, S.C., Han, B., Park, K., Analysis on the current status of targeted drug delivery to tumors. J. Control. Release 164 (2012), 108–114, 10.1016/j.jconrel.2012.07.010.
37. [37] Stirland, D.L., Matsumoto, Y., Toh, K., Kataoka, K., Bae, Y.H., Analyzing spatiotemporal distribution of uniquely fluorescent nanoparticles in xenograft tumors. J. Control. Release 227 (2016), 38–44, 10.1016/j.jconrel.2016.02.016.
38. [38] Matsumoto, Y., Nichols, J.W., Toh, K., Nomoto, T., Cabral, H., Miura, Y., Christie, R.J., Yamada, N., Ogura, T., Kano, M.R., Matsumura, Y., Nishiyama, N., Yamasoba, T., Bae, Y.H., Kataoka, K., Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol., 2016, 10.1038/nnano.2015.342 (advance online publication).
39. [39] Seki, T., Fang, J., Maeda, H., Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 100 (2009), 2426–2430, 10.1111/j.1349-7006.2009.01323.x.
40. [40] Venditto, V.J., Szoka, F.C. Jr., Cancer nanomedicines: so many papers and so few drugs!. Adv. Drug Deliv. Rev. 65 (2013), 80–88, 10.1016/j.addr.2012.09.038.